ArticleBMC complementary medicine and therapies2025
Effectiveness and safety analysis of Qifu Yixin Prescription for the treatment of heart failure with preserved ejection fraction: study protocol for a randomized, double-blind, placebo-controlled clinical trial.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect and Safety of Xinfuli Granules in Chronic Heart Failure with Qi Deficiency and Blood Stasis: A Single-Center Randomized Controlled Trial.Chinese journal of integrative medicine · 2026Trial
- Efficacy and safety of Shengxian Yixin Granule for treating heart failure with preserved ejection fraction: a study protocol for a multicenter, randomized, double-blind, placebo-controlled trial.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHeart failure with preserved ejection fraction (HFpEF) has a high prevalence and risk of mortality, which is still on the rise. Current drug therapies are ineffective, making the development of new drugs for HFpEF particularly important. Qifu Yixin prescription (QYP) has a 20-year history of treating HF, and we have observed positive clinical effects of QYP on HFpEF. However, high-level clinical evidence is lacking. Therefore, a standardized randomized controlled trial (RCT) is necessary to evaluate its clinical effectiveness and safety. METHODS AND ANALYSIS: This study was a randomized, double-blind, placebo-controlled, single-center trial. Participants with HFpEF were randomized in a 1:1 ratio to either the QYP or placebo group for a period of 12 weeks, according to a random number table. The follow-up period lasted for 12 weeks after drug discontinuation. The primary outcome was the change in NYHA classification from baseline to 24 weeks. Secondary outcomes include changes in NT-proBNP, BNP, echocardiographic indices, traditional Chinese medicine symptomatic score scale (TCMSSS), 6-minute walk test (6MWT), Minnesota living with heart failure questionnaire (MLHFQ), Kansas City cardiomyopathy questionnaire (KCCQ), HF readmission rate, cardiovascular mortality, and composite outcomes to evaluate the clinical effectiveness of QYP in treating HFpEF. The safety of QYP will be evaluated through blood, urine, and stool routine tests, liver and kidney function assessments, electrolytes, and electrocardiograms. DISCUSSION: This study will provide standardized, high-quality evidence-based medical support for the clinical application of QYP and facilitate the development of new drugs for HFpEF.
trial registrationhttp://www.chictr.org.cn . Trial number: ChiCTR2400088641. Registered on 22 Aug 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.